![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
M Hohenegger, M Matyash, K Poussu, A Herrmann-Frank, S Sarkozi, F Lehmann-Horn and M Freissmuth
Institute of Pharmacology, University of Vienna, Austria. martin.hohenegger@univie.ac.at
Ca2+ release from skeletal muscle sarcoplasmic reticulum is activated by adenine nucleotides and suramin. Because suramin is known to interact with ATP-binding enzymes and ATP receptors (P2-purinergic receptors), the stimulation by suramin has been postulated to occur via the adenine nucleotide-binding site of the ryanodine receptor/Ca2+- release channel. We tested this hypothesis using suramin and the following suramin analogs: NF037, NF018, NF023, and NF007. The suramin analogs stimulate the binding of [3H]ryanodine binding to sarcoplasmic reticulum membranes with the following rank order of potency: suramin (EC50 = approximately 60 microM) > NF037 (EC50 = approximately 150 microM) > NF018 > NF023 > NF007. The suramin-induced stimulation occurs via a myoplasmic binding site on the ryanodine receptor as confirmed by binding experiments and single-channel recordings with the purified protein. This binding site is different than that for ATP, a conclusion that is supported by the following observations: (i) Suramin stimulates the association rate and inhibits the dissociation rate of [3H]ryanodine, whereas ATP analogs increase only the on-rate. (ii) In the presence of suramin but not of ATP analogs, [3H]ryanodine binding is resistant to the inhibitory effect of millimolar Mg2+ and Ca2+. (iii) ATP analogs and suramin have an additive effect on [3H]ryanodine binding. (iv) Affinity labeling of the purified ryanodine receptor with 2',3'-dialdehyde [alpha-32P]ATP or after in situ oxidation of [gamma- 32P]ATP is not affected by suramin. Thus, our results show that suramin acts as a direct and potent stimulator of the ryanodine receptor but that this action is mediated via a binding site different from that for adenine nucleotides.
This article has been cited by other articles:
|
|
 |
|
  S. A. Kempson, J. M. Edwards, A. Osborn, and M. Sturek Acute inhibition of the betaine transporter by ATP and adenosine in renal MDCK cells Am J Physiol Renal Physiol, July 1, 2008; 295(1): F108 - F117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sacher, L. Weigl, M. Werner, C. Szegedi, and M. Hohenegger Delineation of Myotoxicity Induced by 3-Hydroxy-3-methylglutaryl CoA Reductase Inhibitors in Human Skeletal Muscle Cells J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1032 - 1041. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. O'Neill, M. M. Sakowska, and D. R. Laver Regulation of the Calcium Release Channel from Skeletal Muscle by Suramin and the Disulfonated Stilbene Derivatives DIDS, DBDS, and DNDS Biophys. J., March 1, 2003; 84(3): 1674 - 1689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Hill and R. Sitsapesan DIDS Modifies the Conductance, Gating, and Inactivation Mechanisms of the Cardiac Ryanodine Receptor Biophys. J., June 1, 2002; 82(6): 3037 - 3047. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Suko, G. Hellmann, and H. Drobny Short- and Long-Term Functional Alterations of the Skeletal Muscle Calcium Release Channel (Ryanodine Receptor) by Suramin: Apparent Dissociation of Single Channel Current Recording and [3H]Ryanodine Binding Mol. Pharmacol., March 1, 2001; 59(3): 543 - 556. [Abstract] [Full Text]
|
|
|
|
|
|
M. Klinger, M. Freissmuth, P. Nickel, M. Stäbler-Schwarzbart, M. Kassack, J. Suko, and M. Hohenegger Suramin and Suramin Analogs Activate Skeletal Muscle Ryanodine Receptor via a Calmodulin Binding Site Mol. Pharmacol., March 1, 1999; 55(3): 462 - 472. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
